Business Wire

CA-BEHAVIOSEC

16.6.2021 09:02:06 CEST | Business Wire | Press release

Share
BehavioSec Granted U.S. Patents for Mobile Authentication and Social Engineering Detection

BehavioSec, the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced the successful grant of two additional U.S. patents for its innovative method of verifying user identity and detecting fraud. Since its 2008 founding, BehavioSec has successfully been granted 24 U.S. patents, demonstrating the company’s continual commitment to the innovation and development of behavioral biometrics technology. With this new addition to their patent portfolio, BehavioSec technology can better protect digital identities and consumers on mobile devices from increasingly sophisticated, social engineering attacks – helping stop fraud before the damage is done.

Today, BehavioSec already protects over 180 million people and 20 billion annual transactions across the globe. But as mobile devices continue to increase as a means of conducting financial transactions and accessing account information, consumers and institutions are often trading security and placing more value on the convenience and experience of using them. The new BehavioSec patent US20200074053A1 offers a leap forward in protecting the over 3 billion Android devices in use today . The technology behind this patent allows BehavioSec customers to double the actionable intelligence gleaned from each Android keystroke – without friction, latency, or intrusive data collection. This new technology also instantly matches mobile digital identities against their inherent and unique behavioral biometrics profiles – securing them from fraud like banking trojans, remote access attacks, device theft, and social engineering scams.

For social engineering scams (when legitimate customers are tricked or coached into fraudulent transactions), the new BehavioSec patent US20210117979A1 improves the detection and blocking of these scams at scale. It is a further advancement of the company’s 2019 patent US20200118138A1 that enhanced accuracy and added new methods of detection on mobile devices. With this defensive layer, institutions have greater sensitivity and visibility into subtle behavioral anomalies resulting from stress, hesitation, and duress, which are often key indicators that an attack like voice phishing or authorized push payment (APP) fraud is occurring. These types of fraud methods are typically invisible to traditional methods like device fingerprinting or knowledge-based challenges and can only be detected at scale by employing continuous authentication using frictionless technologies like behavioral biometrics.

“In order to reduce fraudulent activity, customers need to be protected where it matters most, their digital identity,” said Neil Costigan, CEO at BehavioSec. “These additions to our patent portfolio are geared towards increasing visibility and improving detection capabilities to offer our customers the most comprehensive security, fighting fraud before it happens.”

Today’s news comes on the heels of BehavioSec announcing SOC 2 compliance certification and new platform features (version 5.4) that boost enrollment speed, performance, and mobile fraud detection capabilities. For more information on the BehavioSec behavioral biometrics platform and how it safeguards users, visit www.behaviosec.com .

About BehavioSec

BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today.

Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.

Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye